General Instructions for CRF 3 Rev H To be completed at each follow up visit Patient Identification and Group Date of Visit Assessment performed physician.

Slides:



Advertisements
Similar presentations
Medical Coding Chapter 3.
Advertisements

CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS
AEs, SAEs, and EAEs – An Overview
General Guidelines.  Term first-listed diagnosis, rather than principal diagnosis  Outpatient Surgery: Reason for surgery ◦ Even if surgery is cancelled.
ADVERSE EVENT REPORTING
Advances and Emerging Therapy for Lung Cancer
Focused on Pulmonology and Hepatology
CMS Form 2728 ESRD Medical Evidence Report
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
Lynda Laff, RN, BSN, COS-C Laff Associates Consultants in Home Care & Hospice Phone: (843) Website:
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
History – Putting Enough In, Leaving the Right Stuff Out, Making it Legible, & Getting Done! The Hardest Element to Document Effectively - Making it Relatively.
Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.
Breast Cancer Reimbursement Policy in Taiwan Mao-Ting Sheen Director Bureau of National Health Insurance Department of Health, Executive Yuan November.
Investigator Meeting January 2010 Protocol Review and Refresher.
Case Report Form Start-up Meeting March 25, 2010 Kingston, ON.
10 Rights of Medication Administration
PAIN ASSESSMENT PURPOSE  To provide guidelines for the appropriate identification and assessment of patients who may experience pain.
Billing Agent. Pre-Application Checklist Introduction to IMPACT and Key Terms Application Process Starting an Application The Business Process Wizard.
Pharmacy Administration Issues and thoughts Jürgen Brandstätter.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Casefinding & Follow-Up Dolores E. McCord, RHIT, CTR Piedmont Hospital Atlanta, Georgia.
Study Design. Study Designs Descriptive Studies Record events, observations or activities,documentaries No comparison group or intervention Describe.
SECTION I ACTIVE DIAGNOSES June 3, PM. Objectives Understand this section helps generate an updated, accurate picture of the resident’s current.
SAE Reporting Judy Breed, BA, RN June, 2011 CONFIDENTIAL.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
Sarah Sabol. PARS Who: ACCME What: Program and Activity Reporting System When: Annually, by March 31 Why?: Helps ACCME and providers demonstrate the size,
Andrace DeYampert Bethany Lane Samkeliso Mawocha ProTECT III Investigator Meeting November 12-14, 2012.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Entering Data into Complication fields in the CDB October 15, 2014 Maryland Department of Health and Mental Hygiene Prevention and Health Promotion Administration.
SMART Study Closeout Washington ICC Meeting 03 June 2007.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
RECIST Overview.
Phase II in Second Line NSCLC DefinitionPhase II: BI 6727 vs. BI 6727+pemetrexed vs. pemetrexed in second line advanced NSCLC Early stopping.
Hospital Practice 5 The Grieving Process. Grieving ? Grief - noun Grief - noun Grieving – adjective Grieving – adjectiveSynonyms Inconsolable Anguished.
CTRP User Call January 8, 2014 Gene Kraus CTRP Program Director.
Unified Case Management Treatment Plan Training June 2008.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
Active Surveillance for Adverse Drug Events Dan Budnitz, MD, MPH National Center for Injury Prevention & Control November 9, 2004 Collaborative Effort.
Investigator’s Meeting
Windy Newton, ONGSD Program Contact: Gretta (502) Gretta Hylton BOY July 24- AM………………………Begins 9:45 ET.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
 Define Survivorship  Demonstrate understanding of the history of cancer survivorship  State the requirements of the Commission on Cancer of the American.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
SECTION I ACTIVE DIAGNOSES January 14, PM.
By Dr. Ali Abd El-Monsif Thabet.  There are basic requirement for all PT services: (1) Physician order, (2) Evaluation, (3) Plan of care, (4) Ongoing.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outcome of Salvage Total Laryngectomy Following Organ.
BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.
CACI Proprietary Information | Date 1 PD² v4.2 Increment 2 SR13 and FPDS Engine v3.5 Database Upgrade Name: Semarria Rosemond Title: Systems Analyst, Lead.
A quick “how-to” for employees and visitors. Step 1: Finding TRAIN Start at the ES&H Section’s home page (see URL at bottom of slide) Mouse-over “ES&H.
Pharmacy Health Information Technology Collaborative Presenter: Shelly Spiro RPh, FASCP Pharmacy HIT Collaborative, Executive Director.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Slide 1 Copyright © 2014 by Saunders, an imprint of Elsevier Inc. CHAPTER 9 ICD-9-CM OUTPATIENT CODING AND REPORTING GUIDELINES.
1 HOPE Product Use Management: HIV Infection no rapid test(s) positive CONTINUE product. HOLD product pending confirmatory testing. PERMANENTLY DISCONTINUE.
HOW TO ENTER EARLY WITHDRAWAL DATA
FHIR Adverse Event Resource
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Audit Update LUNG-MAP Rose Ermete, Rn, bsn, ocn, ccrp
Pharmacy practice experience I
DO NOT OPEN YOUR BINDER UNTIL INSTRUCTED
Screening Epoch Disposition eCRF
Adverse Event Reporting _____________________________
Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.
Serious Adverse Event Reconciliation
Presentation transcript:

General Instructions for CRF 3 Rev H To be completed at each follow up visit Patient Identification and Group Date of Visit Assessment performed physician by. IMPORTANT OUTCOME MEASURE Provide start and stop date of adjuvant therapy. This should be completed at each visit until patient no longer receiving adjuvant therapy. Disease free? Recurrence? IMPORTANT OUTCOME MEASURE Verify CRF is Rev H Date of Mammogram Radiation Recall Reaction: May occur following chemotherapy in the absence of additional radiation therapy. Survival Status If mammogram not performed DO NOT complete this section. If change from previous visit, specify why Attempt to contact patient at least 3x prior to entering as Lost to F/U.

General Instructions for CRF 4 – Adverse Events To be completed at each follow up visit Patient Identification and Group Date of Visit Describe all adverse events using medical terminology, ie, desquamation, pain in breast, drainage, etc. using definitions provided for in coding. Other Events Adverse Event Example: New event of breast pain occurs on 6/4/04. A start date will be entered but if it is not resolved, it will be checked as Under Observation. Adverse Event Example: Erythema starts on 5/6/04 and is still present at next visit. You will list it again and check ongoing. You do not need to repeat the start date as the event is ongoing. Adverse Event? YES or NO See Definitions CRF 4, pg 2 Is event ongoing from last visit? Not a new event? Is this a Serious AE? Death or threat to life, permanent impairment, requires medical or surgical Intervention to preclude permanent impairment Is the event under observation? Not resolved? Provide start and stop date Intervention: Be specific

Adverse Event Definitions To be used as a guide to completing CRF 4, Page 1